Magical Trade
Saturday, September 23, 2023
  • Home
  • Trade News
  • Email Whitelisting
  • Privacy Policy
No Result
View All Result
  • Home
  • Trade News
  • Email Whitelisting
  • Privacy Policy
No Result
View All Result
Magical Trade
No Result
View All Result
Home Trade News

Pfizer says its Covid pill with HIV drug cuts the risk of hospitalization or death by 89%

by
November 5, 2021
in Trade News
0
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

RELATED POSTS

Berkshire Sells 4.8 Million Shares of HP; More Sales Could be Coming

Which States Don’t Tax Social Security Benefits?

A person walks past the Pfizer building in New York City, March 2, 2021.

Carlo Allegri | Reuters

Pfizer said Friday that its easy-to-administer Covid-19 pill, used in combination with a widely used HIV drug, cut the risk of hospitalization or death by 89% in high-risk adults who’ve been exposed to the virus.

It’s now the second antiviral pill behind Merck‘s to demonstrate strong effectiveness for treating Covid at the first sign of illness. If cleared by regulators, it would likely be a game changer in the ongoing global pandemic fight. Pfizer said it plans to submit its data to the Food and Drug Administration “as soon as possible.”

Pfizer’s pill, scientifically known as PF-07321332, is part of a class of medicines called protease inhibitors and works by inhibiting an enzyme the virus needs to replicate in human cells. Protease inhibitors are used to treat other viral pathogens such as HIV and hepatitis C.

The HIV drug helps slow the metabolism, or breakdown, of Pfizer’s pill in order for it to remain active in the body for longer periods of time at higher concentrations, the company said.

The company said its data on the drug is based on a mid-to-late stage study of 1,219 adults who had at least one underlying medical condition and a laboratory-confirmed infection within a five-day period. Participants were also given a low dose of ritonavir, a medication commonly used in combination treatments for HIV.

Pfizer said there were six hospitalizations and zero deaths out of the 607 trial participants who received the pill in combination with the HIV drug within five days of symptom onset. That compares with 41 hospitalizations and 10 deaths out of the 612 people who received a placebo.

“These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer CEO Albert Bourla said in a statement.

Unlike Gilead Sciences‘ intravenous drug remdesivir, Pfizer’s and Merck’s drugs can be taken by mouth. While vaccinations remain the best form of protection against the virus, health experts hope pills like these will keep the disease from progressing in those who do get infected and prevent trips to the hospital.

Merck and Ridgeback Biotherapeutics said Oct. 1 that they’ve developed a drug that, when administered alone, reduces the risk of hospitalization or death by around 50% for patients with mild or moderate cases of Covid.

The antiviral pill made by Merck was approved by Britain’s medicines regulator on Thursday.

June Raine, chief executive of the U.K.’s Medicines and Healthcare products Regulatory Agency, said that Merck’s pill will greatly facilitate the treatment of Covid, a disease that has killed more than 5 million people globally and caused tremendous strain on health systems.

Bourla told CNBC in April that Pfizer’s pill could be available to Americans by the end of this year.

ShareTweetPin

Related Posts

Berkshire Sells 4.8 Million Shares of HP; More Sales Could be Coming

by
September 23, 2023
0

Which States Don’t Tax Social Security Benefits?

by
September 23, 2023
0

Schedule for Week of September 24, 2023

by
September 23, 2023
0

Legendary investor Jeremy Grantham calls Elon Musk a ‘wonderful propagandist’ and warns home prices will fall 30%. Here are the best 10 quotes from a new interview.

by
September 23, 2023
0

OnlyFans Has Minted A New Group Of High Earners And Millionaires, Here is Where They Are Investing Their Money

by
September 23, 2023
0

Next Post

Chart analysts are watching market's big rally since mid-October for signs of exhaustion

Insider buying: Big moves from Intel leaders highlight this week's top-five internal stock purchases

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:



By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

MOST VIEWED

  • Fund manager believes FAANG is dead — says now it’s all about MANTA

    0 shares
    Share 0 Tweet 0
  • Forget Tesla — this auto stock is the one to buy right now, analyst says

    0 shares
    Share 0 Tweet 0
  • Bank of America names its top global tech stocks — including one it says has upside of 100%

    0 shares
    Share 0 Tweet 0
  • This idiot-proof portfolio has beaten traditional stocks and bonds over 50 years

    0 shares
    Share 0 Tweet 0
  • Josh Brown says Nvidia’s potential is ‘scary’ ahead of a potential AI boom

    0 shares
    Share 0 Tweet 0
  • Home
  • Trade News
  • Email Whitelisting
  • Privacy Policy
All rights reserved by www.magicaltrade.net
No Result
View All Result
  • Email Whitelisting
  • Home
  • Privacy Policy

All rights reserved by www.magicaltrade.net